
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRSD216
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
Details : SRSD216 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Hyperlipoproteinemias.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 15, 2025
Lead Product(s) : SRSD216
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRSD107
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of SRSD107 & Enoxaparin in Adults Undergoing TKA
Details : SRSD107 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Venous Thromboembolism.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 24, 2025
Lead Product(s) : SRSD107
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : BioTrack Capital
Deal Size : $50.0 million
Deal Type : Series B Financing
Sirius Raises $50M to Advance siRNA Therapies for Cardiometabolic Diseases
Details : The funds from this round will further advance clinical programs and expand pipeline including SRSD107, which is being evaluated for the treatment of thromboembolic disorders.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 09, 2025
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : BioTrack Capital
Deal Size : $50.0 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirius Shares Promising Phase 1 Data for Factor XI siRNA in Thromboembolic Disorders
Details : SRSD107 is a Factor XI inhibitor siRNA drug candidate, which is currently being evaluated for the treatment of thromboembolic disorders.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA
Details : SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). it specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/an...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants
Details : SRSD107 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thrombosis.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 03, 2023
Lead Product(s) : SRSD107
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
